Dr. Reddy's Laboratories/$RDY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Dr. Reddy's Laboratories
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
- Ticker
- $RDY
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 27,527
- Headquarters
- Hyderabad, India
- Website
- www.drreddys.com
RDY Metrics
BasicAdvanced
$12B
40.07
$0.35
0.25
$0.06
0.45%
Price and volume
Market cap
$12B
Beta
0.25
52-week high
$15.67
52-week low
$11.36
Average daily volume
3.2M
Dividend rate
$0.06
Financial strength
Current ratio
1.926
Quick ratio
1.154
Long term debt to equity
0.03
Total debt to equity
0.186
Dividend payout ratio (TTM)
23.81%
Interest coverage (TTM)
6.67%
Profitability
EBITDA (TTM)
521.488
Gross margin (TTM)
49.49%
Net profit margin (TTM)
8.48%
Operating margin (TTM)
9.11%
Effective tax rate (TTM)
21.69%
Revenue per employee (TTM)
$126,140
Management effectiveness
Return on assets (TTM)
3.34%
Return on equity (TTM)
7.34%
Valuation
Price to earnings (TTM)
40.073
Price to revenue (TTM)
3.397
Price to book
2.91
Price to tangible book (TTM)
4.18
Price to free cash flow (TTM)
138.073
Free cash flow yield (TTM)
0.72%
Free cash flow per share (TTM)
0.103
Dividend yield (TTM)
0.45%
Forward dividend yield
0.45%
Growth
Revenue change (TTM)
-3.60%
Earnings per share change (TTM)
-52.23%
3-year revenue growth (CAGR)
7.32%
10-year revenue growth (CAGR)
8.63%
3-year earnings per share growth (CAGR)
-18.09%
10-year earnings per share growth (CAGR)
10.23%
10-year dividend per share growth (CAGR)
7.18%
What the Analysts think about RDY
Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
Analyst projections of the future price of Dr. Reddy's Laboratories stock.
Bulls say / Bears say
India is a strong growth engine: Q2 revenue rose 17% year on year, and the company’s sales growth outpaced the Indian pharma market. This helps offset weakness in North America. (U.S. Securities and Exchange Commission)
Generic semaglutide could add a near-term growth driver if supply resumes as planned. Management said the API scale-up issue was resolved, with a Canadian relaunch expected by November and launches planned in nine more markets. (CNBC TV18)
The company is building growth beyond standard generics: it won US approval for a rituximab biosimilar, launched sugammadex first-to-market in the US, and its CDMO business generated more than $100 million in trailing 12-month revenue. (U.S. Securities and Exchange Commission)
North America remains a major drag as lenalidomide sales decline: revenue fell 23% year on year in Q2 and 29% in the first half. New launches have not yet offset that drop. (U.S. Securities and Exchange Commission)
Profitability remains under pressure: Q2 gross margin fell to 52.1% from 54.7% a year earlier, while the company said the West Asia crisis was adding about 100 basis points of EBITDA pressure through input and freight costs. (U.S. Securities and Exchange Commission, The Hindu)
A US tariff plan poses a longer-term risk to its thin-margin generics business: the announced two-year exemption is due to give way to 100% duties on imported generic medicines from August 2028. The chief executive said the company could not absorb tariffs of that scale. (CNBC)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
RDY Financial Performance
Revenues and expenses
RDY Earnings Performance
Company profitability
Upcoming events
No upcoming events
RDY News
AllArticlesVideos
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
MarketBeat1 week ago
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Reuters1 month ago
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire2 months ago
Funds containing RDY
Fund name | Fund size | $RDY weighting |
|---|---|---|
Invesco MSCI ACWI Islamic$MWIM | $124M | 0.24% |
Invesco MSCI ACWI Islamic£MWIX | $124M | 0.24% |
Invesco FTSE All-World£FWRG | $4.8B | 0.10% |
Invesco FTSE All-World€FWIA | $4.8B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.